Comparing to other subtypes of breast cancer, the survival of TNBC patients is even worse [4], due to the fact that TNBC does not respond to HER2 or estrogen receptor-directed treatments, and effective targeted therapies remain lacking [5,6]. Here, ERBB2 is linked to breast carcinoma.